Skip to content
  • Facebook
  • Instagram
  • TikTok
  • Mastodon
  • YouTube
  • X
  • Twitch

Scientific Inquirer

  • Everyday Science.
  • Left Brain/Right Brain.
  • Sports.
  • Features.
  • About.
  • Contact.

drug development

  • DAILY DOSE: The WHO declares anti-vaxxers as bad as Ebola
    January 23, 2019

    DAILY DOSE: The WHO declares anti-vaxxers as bad as Ebola

    thebioscienceguy
  • Vaccine made from Llama antibodies appear to confer universal protection
    January 17, 2019

    Vaccine made from Llama antibodies appear to confer universal protection

    scientificinquirer
  • Targeting bacterial enzymes may leas to a new antibacterial strategy
    January 17, 2019

    Targeting bacterial enzymes may leas to a new antibacterial strategy

    scientificinquirer
  • Scientists target P450 enzyme hoping to make better drugs
    January 16, 2019

    Scientists target P450 enzyme hoping to make better drugs

    scientificinquirer
  • Nanoscale carriers show promise in moving mRNA therapy forward
    January 10, 2019

    Nanoscale carriers show promise in moving mRNA therapy forward

    scientificinquirer
  • New breast cancer drug shows promise in large phase III clinical trial
    January 7, 2019

    New breast cancer drug shows promise in large phase III clinical trial

    scientificinquirer
  • Researchers search for the mechanism of tetracycline’s astonishing off-label capabilities
    January 6, 2019

    Researchers search for the mechanism of tetracycline’s astonishing off-label capabilities

    scientificinquirer
  • Low dosages of CBD proves most effective for chronic pain relief
    January 4, 2019

    Low dosages of CBD proves most effective for chronic pain relief

    scientificinquirer
  • Risk of HIV resistance minimal when using ARC vaginal ring, report
    January 2, 2019

    Risk of HIV resistance minimal when using ARC vaginal ring, report

    scientificinquirer
  • Adenosine receptor may offer an alternative treatment for insomnia
    December 28, 2018

    Adenosine receptor may offer an alternative treatment for insomnia

    scientificinquirer
Previous Page
1 … 47 48 49 50 51 … 55
Next Page

Categories

Asia.

North America.

Europe.

Africa.

South America.

Australia.

Science For All, Not Just The Few.

Subscribe to our newsletters. We’ll keep you in the loop.

  • Facebook
  • Instagram
  • TikTok
  • Mastodon
  • YouTube
  • X
  • Twitch
  • Everyday Science.
  • Left Brain/Right Brain.
  • Sports.
  • Features.
  • About.
  • Contact.

Designed with WordPress

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Loading Comments...